• Eng
  • 中文
  • 日本語
  • Span
  • Eng
  • 中文
  • 日本語
  • Span
Menú
Buscar estudios clínicos
Volver a los resultados de la búsqueda
Finalizado/retirado
ID del estudio de Astellas
2215-CL-0603

A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

ID del estudio de Astellas
2215-CL-0603
Id. de ClinicalTrials.gov
NCT04240002
EUCTIS ID
2024-512469-15-00
Id. de EudraCT
2018-002301-61
jRCT ID
N/A
CN CDE ID
N/A
Obtenga más información

Resumen del estudio

The purpose of the phase 1 portion (dose escalation) of the study was to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in sequential combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). The purpose of the phase 2 portion (dose expansion) was to determine complete remission (CR) rates and composite complete remission (CRc) rates after two cycles of therapy. The study also assessed safety, tolerability and toxicities of gilteritinib in combination with FLAG, evaluated FLT3 inhibition, assessed pharmacokinetics (PK), performed serial measurements of minimal residual disease, obtained preliminary estimates of 1-year event free survival (EFS) and overall survival (OS) rate and assessed the acceptability as well as palatability of the formulation.

One cycle was defined as 28 days of treatment. A participant completing 1 or 2 treatment cycles in phase 1 or 2 had the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).

Más información del estudio

Fase
Phase 1/Phase 2
Producto
gilteritinib
Producto
  • gilteritinib
  • fludarabine
  • cytarabine
  • granulocyte colony-stimulating factor (G-CSF)
    • Tipo
    Interventional
    Enmascaramiento
    None (Open Label)
    Número de inscripción
    9
    Mostrar más información del estudio

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Descargar documento(s)
    Plain Language Summary
    Available Language(s): English, French, German, Italian, Spanish
    Descargar documento(s)
    Protocol
    Available Language(s): English
    Descargar documento(s)
    Statistical Analysis Plan (SAP)
    Available Language(s): English
    Descargar documento(s)

    Obtenga más información

    ¿Le gustaría obtener más información sobre los centros del estudio clínico que están reclutando a participantes para el estudio A Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)? Comuníquese con nosotros completando sus datos a la derecha y le responderemos.

    • A caregiver
    • A healthcare provider
    • A parent
    • A patient
    • A patient advocate
    • Alemania
    • Anteriormente Serbia y Montenegro
    • Arabia Saudita
    • Argelia
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Bélgica
    • Bielorrusia
    • Bosnia y Herzegovina
    • Brasil
    • Bulgaria
    • Canadá
    • Chile
    • China
    • Colombia
    • Croacia
    • Dinamarca
    • Egipto
    • Eslovaquia
    • Eslovenia
    • España
    • Estados Unidos
    • Estonia
    • Federación de Rusia
    • Filipinas
    • Finlandia
    • Francia
    • Georgia
    • Grecia
    • Guatemala
    • Hong Kong
    • Hungría
    • India
    • Indonesia
    • Irlanda
    • Islandia
    • Israel
    • Italia
    • Japón
    • Jordania
    • Kazajistán
    • Letonia
    • Líbano
    • Lituania
    • Macedonia
    • Malasia
    • Marruecos
    • México
    • Montenegro
    • Noruega
    • Nueva Zelanda
    • Países Bajos
    • Panamá
    • Perú
    • Polonia
    • Portugal
    • Puerto Rico
    • Reino Unido
    • República Checa
    • República de Corea
    • República de Moldavia
    • República Dominicana
    • Rumania
    • Serbia
    • Singapur
    • Sudáfrica
    • Suecia
    • Suiza
    • Tailandia
    • Taiwán, provincia de China
    • Turquía
    • Ucrania
    • Vietnam

    Al hacer clic en [“Continuar/Enviar”], usted acepta que Astellas se comunique con usted por correo electrónico con información que lo ayude a conectarse con los centros de estudios clínicos. Si bien podemos conectarlo con los centros de estudios clínicos, no podemos responder preguntas sobre ningún tratamiento en investigación por correo electrónico. Su consentimiento para recibir correos electrónicos no es un requisito para participar en un estudio o estudio clínico. Para obtener más información, incluida la forma de cancelar la suscripción en cualquier momento, consulte nuestro Aviso de privacidad y política de cookies.

      Ubicaciones

      Contáctenos
      Contáctenos
      Withdrawn
      Site CA15001
      Montreal, Quebec, Canadá, H3T 1C5
      Contáctenos
      Finalizado
      Site GB44001
      Birmingham, Reino Unido, B4 6NH
      Contáctenos
      Finalizado
      SIte IT39001
      Roma, Italia, 165
      Contáctenos
      Finalizado
      Site DE49004
      Essen, Nordrhein-Westfalen, Alemania, 45147
      Contáctenos
      Withdrawn
      Site DE49003
      Regensburg, Bayern, Alemania, 93053
      Contáctenos
      Withdrawn
      Site GB44003
      Glasgow, Reino Unido, G51 4TF
      Contáctenos
      Withdrawn
      Site IT39002
      Monza, Italia, 20900
      Contáctenos
      Withdrawn
      Site IT39003
      Bologna, Italia, 40138
      Contáctenos
      Withdrawn
      Site DE49001
      Halle (Saale), Sachsen-Anhalt, Alemania, 06120
      Contáctenos
      Withdrawn
      Site ES34003
      Sevilla, España, 41013
      Contáctenos
      Withdrawn
      Site DE49002
      Freiburg, Baden-Württemberg, Alemania, 79106
      Contáctenos
      Finalizado
      Site GB44005
      Cardiff, Reino Unido, CF14 4XW
      Contáctenos
      Withdrawn
      Site GB44006
      Bristol, Reino Unido, BS2 8BJ
      Contáctenos
      Finalizado
      Site ES34001
      Barcelona, España, 08950
      Contáctenos
      Withdrawn
      Site ES34002
      Barcelona, España, 08950
      Contáctenos
      Withdrawn
      Sarah Cannon Research Institute
      Nashville, TN, Estados Unidos, 37203
      Contáctenos
      Withdrawn
      Cincinnati Children's Hospital Medical Center
      Cincinnati, OH, Estados Unidos, 45229
      Contáctenos
      Withdrawn
      The Children's Hospital of Philadelphia (CHOP)
      Philadelphia, PA, Estados Unidos, 19104
      Contáctenos
      Finalizado
      St. Jude Children's Research Hospital
      Memphis, TN, Estados Unidos, 38105
      Contáctenos
      Finalizado
      Site UK44007
      Sutton, Reino Unido
      Contáctenos
      Withdrawn
      Site FR33005
      Paris, Francia
      Contáctenos
      Withdrawn
      Site FR33006
      Paris, Francia
      Contáctenos
      Withdrawn
      Site FR33004
      Marseille cedex 05, Francia
      Contáctenos
      Withdrawn
      Site FR33003
      Bordeaux, Francia
      Contáctenos
      Withdrawn
      Site FR33002
      Vandoeuvre-Lès-Nancy, Francia
      Contáctenos
      Información del estudio
      Estudio de seguimiento
      Edad
      6 Months - 21 Years
      Diamond icon
      Afección
    • Leucemia - LMA
      • Gender icon
      Sexo
      Mujer y hombre
      Calendar icon
      Fechas del estudio
      Sep 2020 - Mar 2025
      Más información del estudio
      Criterios de inclusión
      • Subject is aged ≥ 6 months and < 21 years of age* at the time of signing informed consent and/or assent, as applicable.
        • *For phase 2: Enrollment of subjects from 6 months to less than 1 year and 1 year to less than 2 years will be dependent on the establishment of recommended phase 2 dose (RP2D) in the respective age groups during phase 1.
      • Subject has a diagnosis of acute myeloid leukemia (AML) according to The French–American–British (FAB) classification with ≥ 5% blasts in the bone marrow, with or without extramedullary disease (except subjects with active central nervous system [CNS] leukemia).
        • In the phase 1 portion of the study, subject must be in first or greater relapse or refractory to induction therapy with no more than 1 attempt at remission induction (up to 2 induction cycles).
        • For the phase 2 portion of the study, subject must be in refractory to or at the first hematologic relapse after first-line remission induction AML therapy (up to 2 induction cycles).
      • Subject has fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
        • Myelosuppressive chemotherapy:

        • + For subject who relapses while receiving cytotoxic therapy, at least 21 days must have elapsed since the completion of cytotoxic therapy and prior to screening, unless the subject has recovered earlier than 21 days.

        + Cytoreduction with the following can be initiated and continued for up to 24 hours prior to the start of systemic protocol therapy (cycle 1 day -1).

      • hydroxyurea,
      • low dose cytarabine (100 mg/m^2 per dose once daily for 5 days) or
      • other low dose/maintenance therapies as per local site practice.

        • + Subject who has received other FLT3 inhibitors (e.g., lestaurtinib, sorafenib, etc) is eligible for this study.

      • Hematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor and prior to screening.
      • Biologic (anti-neoplastic agent): at least 7 days must have elapsed since the completion of therapy with a biologic agent and prior to screening. For agents that have known adverse events (AEs) occurring beyond 7 days after administration, this period must be extended beyond the time during which AEs are known to occur.
      • X-ray treatment (XRT):

        • + 14 days must have elapsed for local palliative XRT for CNS chloromas and prior to screening; no washout period is necessary for other chloromas;

        + Prior to screening, 90 days must have elapsed if the subject had a prior traumatic brain injury or has received craniospinal XRT.

      • For subject undergoing hematopoietic stem cell transplant (HSCT), at least 90 days must have elapsed since HSCT and subject must not have active graft-versus-host disease (GVHD).
      • Subject has Karnofsky score ≥ 50 (if the subject is of ≥ 16 years of age) or Lansky score of ≥ 50 (if the subject is < 16 years of age). A score < 50 is acceptable if related to the subject’s leukemia.
      • Subject must meet the following criteria as indicated on the clinical laboratory tests.
        • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x upper limit normal (ULN) for age
        • Total serum bilirubin ≤ 1.5 x ULN for age
        • Estimated glomerular filtration rate of > 60 mL/min/1.73 m^2.
      • A female subject is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:
        • No es una mujer en edad fértil (MEF).

        • OR

      • WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration.
      • Female subject must agree not to breastfeed starting at Screening, and throughout the study period and for 60 days after the final study drug administration.
      • Female subject must not donate ova starting at Screening and throughout the study, and for 180 days after the final study drug administration.
      • A male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 180 days after the final study drug administration.
      • A male subject must not donate sperm during the treatment period and for at least 120 days after the final study drug administration.
      • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 180 days after the final study drug administration.
      • Subject and subject’s parent(s) or legal guardian agrees not to participate in another interventional

        • study while on treatment.

      • Live Vaccines - At least 6 weeks must have elapsed since the administration of the last dose of a live vaccine and prior to the initiation of study treatment (cycle 1, day -1)
      • Phase 1: Subject is positive for FLT3 (ITD and/or tyrosine kinase domain [TKD]) mutation in bone marrow or blood as determined by the local institution.
      • Phase 2: Subject is positive for the FLT3 (ITD) mutation in bone marrow or blood as determined by the local institution.
      MaximizeCriterios de exclusión
      • Subject has active CNS leukemia.
      • Subject has uncontrolled or significant cardiovascular disease, including:
        • Diagnosed or suspected congenital long QT syndrome or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes (TdP)); any history of arrhythmia will be discussed with the sponsor prior to subject’s entry into the study
        • Prolonged Fridericia's Correction Formula (QTcF) interval on pre-entry electrocardiogram (ECG) (≥ 450 ms)
        • Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)
        • Heart rate < 50 beats/minute on pre-entry ECG
        • Uncontrolled hypertension
        • Complete left bundle branch block
      • Subject has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The subject needs to be off pressors and have negative blood cultures for 48 hours.
      • Subject is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
      • Subject has active clinically significant GVHD or is on treatment with immunosuppressive drugs for treatment of active GVHD, with the exception of subjects being weaned from systemic corticosteroids where the subject is receiving ≤ 0.5 mg/kg of prednisone (or equivalent) daily dose for prior GVHD. Subject has received calcineurin inhibitors within 4 weeks prior to screening, unless used as GVHD prophylaxis.
      • Subject has active malignant tumors other than AML.
      • Subject has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance; interfere with consent, study participation, follow-up or interpretation of study results.
      • Subject has hypokalemia and/or hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]). Repletion of potassium and magnesium levels during the screening period is allowed.
      • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A/P-glycoprotein (P-gp).
      • Subject is known to have human immunodeficiency virus infection.
      • Subject has active hepatitis B or C, or other active hepatic disorder.
        • Subjects with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B DNA are not eligible.
        • Subjects with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if hepatitis B DNA is undetectable.
        • Subjects with antibodies to hepatitis C virus will be eligible if hepatitis C RNA is undetectable.
      • Subject must wait for at least 5 half-lives after stopping therapy with any investigational agent and before starting gilteritinib.
      • Subject has a known or suspected hypersensitivity to gilteritinib, cytarabine, fludarabine, granulocyte colony-stimulating factor (G-CSF) or any components of the formulation used.

      Preguntas frecuentes

      ¿Los estudios clínicos son solo para personas con cáncer avanzado?

      Si bien algunos estudios clínicos pueden enfocarse en cánceres más avanzados, muchos estudios están abiertos para pacientes con cáncer en diferentes etapas. Cada estudio tiene reglas que establecen quiénes pueden participar. Por ejemplo, quizás solo puedan participar pacientes de un grupo de edad determinado o aquellos que tengan un tipo determinado de tumor.

      ¿Será necesario que interrumpa mi tratamiento actual para participar en un estudio clínico?

      A veces los investigadores quieren que los participantes sigan recibiendo sus tratamientos actuales durante un estudio clínico. En otras ocasiones, es posible que deba interrumpir sus tratamientos actuales durante un tiempo. Si el tratamiento en investigación no funciona, siempre puede volver a su plan de tratamiento original.

      ¿Debería preocuparme la posibilidad de recibir placebo?

      En los estudios clínicos oncológicos, solo se usa placebo si no hay otro tratamiento disponible para ese tipo de cáncer. Esto ayuda a comparar un tratamiento en investigación con el placebo. Los placebos rara vez se usan en estudios oncológicos, porque en su lugar generalmente se administra el mejor tratamiento disponible, que se denomina “estándar de atención”.

      ¿Necesito una derivación de mi médico para participar en un estudio?

      Es posible que su médico no conozca todas las oportunidades de participación en estudios clínicos que usted tiene a su disposición. Hable con su médico o con otro profesional de la salud sobre la información que encuentre en relación con un estudio clínico. Podrán ayudarlo a decidir si el estudio clínico es adecuado para usted. Si no encuentra ninguna opción en este sitio web, le recomendamos que visite un registro público en línea, por ejemplo, clinicaltrials.gov para conocer los diversos estudios clínicos que están disponibles.

      Seguir leyendo

      1

      ¿Qué son los estudios clínicos?

      Encuentre un estudio
      2

      ¿Por qué son importantes los estudios clínicos?

      Más información
      3

      ¿Por qué participar en un estudio clínico?

      Descubra más